Trial Profile
A Multiple-Site, Randomized, Double-Blind, Placebo-Controlled, Single Ascending Dose (SAD) Study to Assess the Safety and Tolerability of Inhaled SNSP113 in Healthy Male Subjects (Part A) and Subjects With Stable Cystic Fibrosis (Part B)
Status:
Discontinued
Phase of Trial:
Phase I
Latest Information Update: 20 Apr 2023
Price :
$35
*
At a glance
- Drugs SNSP 113 (Primary)
- Indications Cystic fibrosis
- Focus Adverse reactions; First in man; Therapeutic Use
- Sponsors Anagram Therapeutics
- 04 Apr 2023 According to an Anagram Therapeutics media release, Synspira changed its name to Anagram Therapeutics.
- 23 May 2018 Status changed from recruiting to discontinued due to successful completion of Part A. Company decision to end early.
- 03 Jan 2018 According to a Synspira media release, the phase Ia portion of this trial in healthy volunteers has been completed, and it will advance into stable CF patients in 2018.